Aust N Z J Obstet Gynaecol. 1996 Feb;36(1):55-60. doi: 10.1111/j.1479-828x.1996.tb02924.x.
A multicentre, open, randomized comparison of depot goserelin versus danazol to treat endometriosis was undertaken in 9 Australian/New Zealand centres. The study compared the effects of the 2 drugs on subjective and objective parameters in women with symptomatic and/or infertility associated endometriosis. The duration of treatment was 24 weeks with either depot goserelin acetate, 3.6 mg, subcutaneously at 4-weekly intervals or danazol, 600 mg/day. As shown in previous studies, depot goserelin and danazol were equally effective in reducing endometriosis scores and pain. Patients in our study showed considerably more intolerance of study drugs, particularly danazol, than women in American and European reports: 19 of 36 women randomized to danazol in our study failed to complete 6 months therapy, because of adverse events (9/36) or because of unwillingness to continue with therapy (8/36). Consumer satisfaction with medical treatment for endometriosis was an important issue in this study.
在澳大利亚/新西兰的9个中心开展了一项多中心、开放性、随机对照试验，比较长效戈舍瑞林与达那唑治疗子宫内膜异位症的效果。该研究比较了这两种药物对有症状和/或与不孕相关的子宫内膜异位症女性主观和客观指标的影响。治疗持续时间为24周，治疗方案为：每4周皮下注射一次3.6mg醋酸戈舍瑞林缓释植入剂，或每日服用600mg达那唑。如先前研究所示，长效戈舍瑞林和达那唑在降低子宫内膜异位症评分和疼痛方面同样有效。与美国和欧洲报告中的女性相比，我们研究中的患者对研究药物，尤其是达那唑的不耐受情况要严重得多：在我们的研究中，随机分配到达那唑组的36名女性中有19名未能完成6个月的治疗，原因是出现不良事件（9/36）或不愿继续治疗（8/36）。在这项研究中，患者对子宫内膜异位症治疗的满意度是一个重要问题。
